{"classes":["PERSON","NORP","FAC","ORG","GPE","LOC","PRODUCT","EVENT","WORK_OF_ART","LAW","LANGUAGE","DATE","TIME","PERCENT","MONEY","QUANTITY","ORDINAL","CARDINAL"],"annotations":[["Immunex Corp. said its scientists isolated a molecule which may hold potential as a treatment for disruptions of the immune - system , ranging from organ - transplant rejection , to allergies and asthma .",{"entities":[[0,13,"ORG"]]}],["The molecule is the mouse version of a protein called the interleukin - 4 receptor .",{"entities":[[70,73,"CARDINAL"]]}],["IL - 4 is a hormone which directs the growth and function of white blood cells involved in the body 's immune response .",{"entities":[[3,6,"CARDINAL"]]}],["The IL - 4 receptor on the surface of such cells receives the hormone 's message to rally the body 's defense .",{"entities":[[7,10,"CARDINAL"]]}],["But in certain conditions such as autoimmune diseases and allergies and transplant rejection , doctors would like to damp the immune response so such cells do n't touch off harmful inflammatory reactions or cell destruction .",{"entities":[]}],["A soluble form of the receptor might turn off a specific part of the immune response without general immune suppression , the company said .",{"entities":[]}],["The IL - 4 receptor is one of five such receptors to be developed and tested by Receptech Corp. , a spinoff of Immunex , through a proposed $ 30 million initial public offering .",{"entities":[[7,10,"CARDINAL"],[80,95,"ORG"],[111,118,"ORG"],[140,152,"MONEY"]]}],["Immunex will contract with the spinoff to provide the research , development and initial testing of the new agents .",{"entities":[[0,7,"ORG"]]}],["Immunex will have the option to buy back Receptech shares after five years .",{"entities":[[0,7,"ORG"],[41,50,"ORG"]]}]]}